iTeos Therapeutics (NASDAQ:ITOS) Given Outperform Rating at Wedbush

Wedbush restated their outperform rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research report report published on Thursday morning,RTT News reports. Wedbush currently has a $25.00 price objective on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a research note on Friday, November 15th.

iTeos Therapeutics Price Performance

Shares of NASDAQ:ITOS opened at $7.95 on Thursday. The business has a 50-day moving average of $8.79 and a two-hundred day moving average of $13.05. The firm has a market capitalization of $290.26 million, a PE ratio of -2.52 and a beta of 1.37. iTeos Therapeutics has a 12 month low of $7.54 and a 12 month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. As a group, research analysts anticipate that iTeos Therapeutics will post -3.46 earnings per share for the current year.

Insider Activity at iTeos Therapeutics

In related news, CFO Matthew Gall acquired 5,000 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was bought at an average cost of $7.73 per share, with a total value of $38,650.00. Following the acquisition, the chief financial officer now directly owns 65,429 shares in the company, valued at approximately $505,766.17. The trade was a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On iTeos Therapeutics

Several large investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in iTeos Therapeutics during the third quarter valued at approximately $102,000. Geode Capital Management LLC raised its holdings in shares of iTeos Therapeutics by 3.2% during the third quarter. Geode Capital Management LLC now owns 640,350 shares of the company’s stock worth $6,540,000 after purchasing an additional 20,092 shares during the period. XTX Topco Ltd bought a new position in shares of iTeos Therapeutics in the 3rd quarter worth about $186,000. Wellington Management Group LLP boosted its holdings in shares of iTeos Therapeutics by 20.9% in the 3rd quarter. Wellington Management Group LLP now owns 105,769 shares of the company’s stock valued at $1,080,000 after buying an additional 18,255 shares during the period. Finally, State Street Corp grew its position in shares of iTeos Therapeutics by 21.9% during the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock valued at $12,000,000 after buying an additional 211,452 shares during the last quarter. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.